Oncotarget

Meta-Analysis:

Prognostic role of long non-coding RNA TUG1 expression in various cancers: a meta-analysis

Yongping Zhou, Yuxuan Lu, Runmin Li, Nana Yan, Xiding Li and Tu Dai _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:100499-100507. https://doi.org/10.18632/oncotarget.20037

Metrics: PDF 1197 views  |   HTML 2097 views  |   ?  


Abstract

Yongping Zhou1, Yuxuan Lu2, Runmin Li2, Nana Yan3, Xiding Li4 and Tu Dai1

1Department of Hepatobiliary, Wuxi Second Hospital, Nanjing Medical University, Wuxi, China

2School of Medicine, Tongji University, Shanghai, China

3Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China

4Department of General Surgery, Wuxi Second Hospital, Nanjing Medical University, Wuxi, China

Correspondence to:

Tu Dai, email: [email protected]

Xiding Li, email: [email protected]

Keywords: long non-coding RNA TUG1, cancer, prognostic

Received: May 10, 2017     Accepted: July 26, 2017     Published: August 08, 2017

ABSTRACT

Several studies were conducted to explore the prognostic role of long non-coding RNA taurine upregulated gene 1 (lncRNA TUG1) expression in various cancers, with contradictory. This study aims to summarize the prognostic role of lncRNA TUG1 expression in various cancers. Embase, PubMed and Cochrane Library were completely retrieved. The cohort studies focusing on the prognostic role of lncRNA TUG1 expression in various cancers were eligible. The endpoints were overall survival (OS) and clinicopathological parameters. 9 studies involving a total of 1,078 patients were identified. The results showed that high lncRNA TUG1 expression was obviously associated with worse OS when compared to the low lncRNA TUG1 expression (HR = 1.37, 95% CI = 1.07–1.76, P = 0.01; I2 = 85%). However, No distinct relationship was observed between the lncRNA TUG1 expression and age (OR = 0.99, 95% CI = 0.76–1.28, P = 0.92; I2 = 4%), gender (OR = 0.92, 95% CI = 0.70–1.22, P = 0.57; I2 = 0%), diameter (OR = 0.83, 95% CI = 0.34–2.01, P = 0.67; I2 = 85%), smoking (OR = 1.09, 95% CI = 0.37–3.21, P = 0.87; I2 = 73%), TNM stage (OR = 0.60, 95% CI = 0.25–1.43, P = 0.25; I2 = 86%) and lymph node metastasis (OR = 1.07, 95% CI = 0.47–2.45, P = 0.87; I2 = 86%). In conclusion, it was revealed that high lncRNA TUG1 expression is an unfavorable predictor of OS in patients with cancers, and lncRNA TUG1 expression is a promising prognostic biomarker for various cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20037